These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 27215057)

  • 21. [Newly development of phosphate binders in hyperphosphatemic patients with kidney dysfunction].
    Negi S; Yamanaka S; Koreeda D; Yashiro M; Shigematsu T
    Clin Calcium; 2012 Oct; 22(10):1557-66. PubMed ID: 23023637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of phosphate binders in chronic kidney disease.
    Ketteler M; Biggar PH
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphate: a stealthier killer than previously thought?
    Gonzalez-Parra E; Tuñón J; Egido J; Ortiz A
    Cardiovasc Pathol; 2012; 21(5):372-81. PubMed ID: 22425627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?
    Negri AL
    J Nephrol; 2010; 23(6):653-7. PubMed ID: 20349415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are calcium-based phosphate binders ever preferable in dialysis patients?
    Jain N; Reilly RF
    Semin Dial; 2014; 27(3):269-72. PubMed ID: 24620781
    [No Abstract]   [Full Text] [Related]  

  • 26. [Management of hyperphosphatemia in dialysis patients: the role of phosphate binders].
    Malberti F
    G Ital Nefrol; 2010; 27 Suppl 52():S47-54. PubMed ID: 21132662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral phosphate binders in patients with kidney failure.
    Feith GW
    N Engl J Med; 2010 Sep; 363(10):989-90; author reply 990. PubMed ID: 20809852
    [No Abstract]   [Full Text] [Related]  

  • 28. Oral phosphate binders in patients with kidney failure.
    Moe SM; Block GA; Langman CB
    N Engl J Med; 2010 Sep; 363(10):990; author reply 990. PubMed ID: 20830820
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients.
    Cervelli MJ; Shaman A; Meade A; Carroll R; McDonald SP
    Nephrology (Carlton); 2012 Jul; 17(5):458-65. PubMed ID: 22471559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphate management in chronic kidney disease.
    Bhan I
    Curr Opin Nephrol Hypertens; 2014 Mar; 23(2):174-9. PubMed ID: 24445424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphate binders. Is selection determined by price? No.
    Fernández-Giráldez E
    Nefrologia; 2012; 32(2):240-4. PubMed ID: 22466265
    [No Abstract]   [Full Text] [Related]  

  • 32. Sevelamer prescriptions after reporting of the Dialysis Clinical Outcomes Revisited (DCOR) trial findings: An analysis of 5,495 patients receiving maintenance dialysis in Ontario, Canada.
    Weir MA; Jain AK; Gomes T; Juurlink DN; Mamdani M; Li L; Garg AX
    Am J Kidney Dis; 2011 Feb; 57(2):357-9. PubMed ID: 21251552
    [No Abstract]   [Full Text] [Related]  

  • 33. Using concordance with dosing techniques to achieve phosphate control.
    Koester LA; Rothstein M
    Nephrol News Issues; 2013 Nov; 27(12):22, 24, 26-8 passim. PubMed ID: 24354233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of calcium on cardiovascular events in patients with kidney disease and in a healthy population.
    West SL; Swan VJ; Jamal SA
    Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S41-7. PubMed ID: 20089502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is combined calcium/magnesium phosphate binder really noninferior to sevelamer hydrochloride?
    Spasovski G; Vanholder R
    Nephrol Dial Transplant; 2011 Apr; 26(4):1442-3; author reply 1443-4. PubMed ID: 21339309
    [No Abstract]   [Full Text] [Related]  

  • 36. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.
    Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kawasaki S;
    Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel iron-based phosphate binders in patients with chronic kidney disease.
    Shah HH; Hazzan AD; Fishbane S
    Curr Opin Nephrol Hypertens; 2015 Jul; 24(4):330-5. PubMed ID: 26050119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data.
    Sinsakul M; Rodby R; Umanath K; Niecestro R; Dwyer JP
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):705-10. PubMed ID: 25242077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient empowerment in the management of hyperphosphatemia.
    Kuhlmann MK; Hoechst S; Landthaler I
    Int J Artif Organs; 2007 Nov; 30(11):1008-13. PubMed ID: 18067103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].
    Zwiech R; Dryja P; Łacina D; Króliczak V; Chrul S; Kacprzyk F
    Wiad Lek; 2011; 64(1):9-14. PubMed ID: 21812357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.